✦ LIBER ✦

Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies

✍ Scribed by Hindrik Vondeling; Peter Bindslev Iversen

Publisher: Springer
Year: 2004
Tongue: French
Weight: 234 KB
Volume: 5
Category: Article
ISSN: 1618-7598
DOI: 10.1007/s10198-004-0235-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective study of depression and mo

A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study

✍ D. G. Bruce; W. A. Davis; S. E. Starkstein; T. M. E. Davis 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 139 KB

Endothelial dysfunction in geriatric dia

Endothelial dysfunction in geriatric diabetic patients: the role of microalbuminuria in elderly type 2 diabetic patients? A randomized controlled study

✍ Mohamed A. Helaly; Hussein A. Sheashaa; El Sayed Z. Hatata; Ansaf B. Youssef; As 📂 Article 📅 2006 🏛 Springer Netherlands 🌐 English ⚖ 135 KB

Pravastatin compared to bezafibrate in t

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus

✍ C. Rustemeijer; J. A. Schouten; H. J. Voerman; H. E. S. J. Hensgens; A. J. M. Do 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background Both HMG-CoA reductase inhibitors and ®bric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg beza®brate, a ®bric acid deriva

Genes for systemic vascular complication

Genes for systemic vascular complications are differentially expressed in the livers of Type 2 diabetic patients

✍ T. Takamura; M. Sakurai; T. Ota; H. Ando; M. Honda; S. Kaneko 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 406 KB

A comparison of repaglinide and glibencl

A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas

✍ R. Landgraf; H. J. G. Bilo; P. G. Müller 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 103 KB

Financial requirements for the treatment

Financial requirements for the treatment of diabetes in Latin America: implications for the health system and for patients in Mexico

✍ A. Arredondo; E. de Icaza 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 64 KB